Lilly's oral GLP-1 drug Foundayo cleared for prescription in Australia

摘要

Eli Lilly's oral GLP-1 medication orforglipron, sold as Foundayo, has been approved by the Therapeutic Goods Administration and will be available for prescription within days, offering a new option for weight management and type-2 diabetes treatment.

Eli Lilly announced that its oral GLP-1 medication orforglipron, marketed as Foundayo, has been added to the Australian Register of Therapeutic Goods and will be ready for prescription in the coming days. The small-molecule drug is indicated as an adjunct to diet and exercise for chronic weight management and for treating type-2 diabetes in adults. It will be supplied in six dose strengths ranging from 0.8 mg to 17.2 mg and can be dispensed through Lilly’s LillyDirect service as well as community pharmacies.

RACGP President Dr Michael Wright said the approval adds a new therapeutic option, noting that, “It’s a small molecule medication, not a peptide – and this means it’s better absorbed orally and not breaking down in the stomach.” He added that general practitioners are best placed to assess suitability and monitor side effects for patients requiring weight-management or diabetes support.

The Therapeutic Goods Administration specifies that Foundayo is approved for adults with a body-mass index (BMI) over 30, or over 27 with at least one weight-related comorbidity such as hypertension, dyslipidaemia, prediabetes, type-2 diabetes, obstructive sleep apnoea, or cardiovascular disease. It is also approved for type-2 diabetes when metformin is unsuitable or as an add-on therapy. Phase-three trials reported up to a 12.4 % reduction in body weight over 72 weeks at the highest dose, with a safety profile comparable to other GLP-1 receptor agonists and most adverse events being mild to moderate gastrointestinal effects.

Lilly listed retail prices of approximately AU$250 per 30-tablet pack for lower doses and AU$370 for higher doses, noting that final prices are set by individual pharmacies. Dr Wright observed that while the cost appears lower than injectable alternatives, the medication is currently available only on private prescription and has not been listed on the Pharmaceutical Benefits Scheme, raising concerns about equitable access.

The approval follows Novo Nordisk’s earlier confirmation that its oral semaglutide tablet, Wegovy, has also been approved in Australia and is expected to be prescribed later this year.

继续阅读——免费

创建免费账户以关注新闻。无需银行卡。